Find a pharmacy Healthcare professionals Partnering Press TR EN
General health information

D-mannose research: what the 2024 trial found

D-mannose is a sugar investigated because of mechanisms involved in bacterial attachment to urinary tract cells. Controlled studies in people provide information beyond laboratory explanations.

Published by Aymed İlaç · 17 October 2026

What question was tested?

The study published in 2024 recruited 598 women with recurrent urinary tract infections from primary-care practices in the United Kingdom. It examined whether daily D-mannose reduced further episodes of suspected infection leading to medical contact over six months. The comparator was a placebo. [1]

What was the result?

Among participants with outcome data, this occurred in 51.0% of the D-mannose group and 55.7% of the placebo group. The difference was not statistically significant. The trial did not support a preventive benefit for this use in the population studied. [1]

Why is a numerical difference insufficient?

Differences between percentages are interpreted alongside uncertainty and chance variation. A slightly lower percentage in one group does not, by itself, establish an effective intervention. Study design, sample size and confidence intervals help determine how much weight a result can carry. They are part of interpreting the finding rather than optional technical details.

Keeping the result within its scope

This was a prevention study in community-dwelling women with a history of recurrent infections. It did not test treatment of an established infection or every possible combination product. Extending the findings directly to other populations or formulations would go beyond the study; disregarding the negative finding would also misrepresent it. [1, 2]

Why cranberry is assessed separately

Cranberry and its constituents are investigated separately from D-mannose, which is a sugar. Combining ingredients in one product does not allow their separate research findings to be added together as proof of a stronger effect. A useful clinical discussion considers the full formulation, the purpose being studied and the person’s history of confirmed infections. The question is what evidence applies to a particular situation, rather than whether two ingredients share a urinary-health label. [2, 3]

References

  1. Hayward ve ark. d-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women. JAMA Internal Medicine, 2024
  2. EAU Guidelines on Urological Infections, güncel çevrimiçi metin
  3. Williams ve ark. Cranberries for preventing urinary tract infections. Cochrane, 10 Kasım 2023, CD001321.pub7

This article provides general health information. Consult your clinician for individual diagnosis and treatment decisions, and your pharmacist for questions about medicine use.

Published by Aymed İlaç · 17 October 2026